Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Vésale Bioscience has developed a proprietary platform enabling rapid, personalized bacteriophage-based therapies targeting multidrug-resistant bacterial infections. Their “Inteliphage” system leverages an extensive phage library and automated diagnostics (“Phagogram”) to deliver tailored treatments within one day. The company has demonstrated successful treatment of severe cases under compassionate use frameworks and received significant recognition and funding from European innovation bodies. Clinical deployment for broader patient populations is targeted from 2026 onward.[1][2][3]
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Vésale Bioscience.